FierceBiotech
New EHA data reveal how badly Gilead's $4.9B bet on CD47 imploded
Gilead Sciences' abandoned anti-CD47 drug magrolimab was not just ineffective, but could potentially be harmful to patients with untreated high-risk myelodysplastic syndrome, according to new ...
11 hours ago